Search results for "Microtubule dynamics"

showing 4 items of 4 documents

Eribulin (E) and capecitabine (C), a combined treatment schedule in elderly metastatic breast cancer (EMBC): Efficacy and safety evaluation (E&S).

2014

e20513 Background: E mesylate, a nontaxane microtubule dynamics inhibitor, was approved in the U.S in 2010 for the treatment of MBC who have previously received at least 2 MBC chemo regimens, inclu...

OncologyCancer ResearchSchedulemedicine.medical_specialtyMicrotubule dynamicsMesylatebusiness.industrybacterial infections and mycosesmedicine.diseaseMetastatic breast cancerCapecitabinechemistry.chemical_compoundCombined treatmentOncologychemistryInternal medicinepolycyclic compoundsmedicinebacteriaskin and connective tissue diseasesbusinessneoplasmsmedicine.drugEribulinJournal of Clinical Oncology
researchProduct

Multicenter study of the eValuation of Eribulin (E) use in Sicily in metastatic breast cancer (MBC): A Prospective RegistrY (VESPRY trial)

2015

e12565 Background: Eribulin Mesylate is a non taxane microtubule dynamics inhibitor, approved for heavily-pretreated MBC patients (pts). Methods: This is a multicenter, prospective, single arm study for E-treatment of third line in pretreated MBC pts, conducted in 14 oncology centers in Sicily. All pts had received two previous chemotherapy regimens for MBC. Pts received E at 1.23 mg/m2 on days 1,8 every 3 weeks until progression. Primary Endpoints: overall response rate (ORR) according to the site of metastases and safety. Secondary objectives: Progression-free survival (PFS) and ORR according to different subtypes. PFS curve was estimated using the Kaplan-Meier method. Multivariable logi…

Eribulin MesylateGynecologyOncologyCancer Researchmedicine.medical_specialtyTaxaneMicrotubule dynamicsbusiness.industryHematologymedicine.diseaseMetastatic breast cancerSurgerychemistry.chemical_compoundOncologychemistryInternal medicineMedicinebusinessEribulinAnnals of Oncology
researchProduct

Combination of eribulin (E) and capecitabine (C) in elderly metastatic breast cancer (MBC): Update of a new option suitable in older elderly.

2015

9540 Background: E mesylate, a nontaxane microtubule dynamics inhibitor is widely prescribed for MBC pts pretreated with at least 1-2 lines of chemotherapy, including anthracyclines and taxanes (A&...

OncologyCancer Researchmedicine.medical_specialtyChemotherapyMicrotubule dynamicsMesylatebusiness.industrymedicine.medical_treatmentPharmacologymedicine.diseaseMetastatic breast cancerCapecitabinechemistry.chemical_compoundOncologychemistryInternal medicinemedicinebacteriabusinessmedicine.drugEribulinJournal of Clinical Oncology
researchProduct

Synthesis of N-acyl Derivatives of Aminocombretastatin A-4 and Study of their Interaction with Tubulin and Downregulation of c-Myc.

2021

11 p.-9 fig.-4 tab.

Down-RegulationAntineoplastic AgentsMicrotubule dynamicsStructure-Activity RelationshipDownregulation and upregulationMicrotubuleTubulinCell Line TumorDrug DiscoveryHumansMTT assayAminocombretastatin A-4Cell ProliferationbiologyChemistryCell growthIn vitroTubulin ModulatorsMolecular Docking SimulationTubulinc-MycBiochemistryCell cultureDocking (molecular)biology.proteinDrug Screening Assays AntitumorAnti-proliferative activityAnti-mitoticMedicinal chemistry (Shariqah (United Arab Emirates))
researchProduct